The release of interim data from a clinical trial is a significant event for a biotech company like Indaptus Therapeutics. However, the lack of specifics in the announcement may lead to uncertainty among investors, potentially impacting the company's stock price. Until more details are released, it's difficult to predict the direction of the impact.